Companion diagnostics are transforming cancer care from a one-size-fits-all approach to precise, data-driven therapy selection. The South America Companion Diagnostics Oncology Market is expanding as infrastructure investment grows alongside clinical training initiatives.

Similarly, the Spain Companion Diagnostics Oncology Market is integrating oncology testing into standard clinical pathways, improving early detection and survival outcomes.

The US Companion Diagnostics Oncology Market continues to innovate with next-generation sequencing, liquid biopsy platforms, and real-world evidence tools that enhance predictive accuracy. These advances are making precision oncology not just a concept, but a practical reality for patients around the world.

FAQs

Q1. What technologies are used in companion diagnostics?
A. Genetic sequencing, PCR, immunohistochemistry, and liquid biopsy technologies.

Q2. Can companion diagnostics predict treatment success?
A. Yes, they help determine which therapy is most likely to benefit a patient.

Q3. Is companion diagnostics part of standard cancer care?
A. It increasingly is, especially for targeted therapies.